Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer

The anti-programmed cell death receptor 1 (anti-PD-1) immunotherapy has been recommended in several treatment scenarios of metastatic urothelial cancer (UC), including as a maintenance therapy after first-line chemotherapy. However, the PD-1 inhibitor accelerates tumor growth occasionally, causing h...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Yangchun, He, Huiying, Wang, Mopei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420926/
https://www.ncbi.nlm.nih.gov/pubmed/34527790
http://dx.doi.org/10.4103/apjon.apjon-2142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420926/
https://www.ncbi.nlm.nih.gov/pubmed/34527790
http://dx.doi.org/10.4103/apjon.apjon-2142

Ejemplares similares